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Inquilinus limosus 
and Cystic Fibrosis
To the Editor: Inquilinus limo-
sus, a new multidrug-resistant species, 
was reported in 1999 as an unidenti-
fi ed gram-negative bacterium in a lung 
transplant patient with cystic fi brosis 
(CF) (1). This species was later char-
acterized by the description of 7 new 
isolates of I. limosus and 1 isolate of 
Inquilinus sp. (2). Infections and colo-
nizations by I. limosus have been doc-
umented mainly in adolescent or adult 
patients with CF. To date, 8 clinical 
cases have been described in Germany 
(3,4), 1 case in the United States (1), 5 
cases in France (5), and 1 case in the 
United Kingdom (6) (Table). Only 1 
isolate of Inquilinus sp. has been re-
covered from blood samples of a pa-
tient without CF who had prosthetic 
valve endocarditis (7). 
Because this bacterium is not re-
corded in all commercial identifi cation 
system databases currently available, 
a longitudinal study for I. limosus 
detection with a new real-time PCR 
assay with a Taqman probe (Applied 
Biosystems, Foster City, CA, USA), 
that targets the 16S rRNA gene, has 
been developed and compared with 
the culture isolation. Primers il1d (5′-
TAATACGAAGGGGGCAAGCGT-
3′) and il1r (5′-CACCCTCTCTTGGA
TT CAAGC-3′) and probe ilProbe 
(6FAM-GGTTCGTTGCGTCAGAT
GTGAAAG-TAMRA), which were 
used in this study, were designed on 
the basis of multisequence alignment 
of all I. limosus 16S rDNA sequences 
available in the GenBank database. 
To confi rm specifi city, the prim-
ers and probe were checked by using 
the BLAST program (www.ncbi.nlm.
nih.gov/blast/Blast.cgi) and also by 
using suspension of several bacteria 
recovered habitually in patients with 
CF. For sensitivity of the Taqman PCR 
assay (Applied Biosystems), the mini-
mal CFU detectable was 2 CFU/PCR. 
From January 2006 through June 
2007, 365 sputum samples recovered 
from 84 children and 61 adults with 
CF and 71 sputum samples recovered 
from 54 patients without CF were 
screened blindly for I. limosus. By us-
ing our real-time PCR, we detected 9 
I. limosus-positive samples from 4 pa-
tients with CF (Table); 8 of these sam-
ples were also culture positive. How-
ever, all sputum samples from patients 
without CF were negative. In 1 patient 
(Table, case 17), I. limosus was detect-
ed by using real-time PCR 3 months 
before the culture was positive. Ret-
rospectively, the patient’s medical fi le 
was rechecked and his clinical respira-
tory condition worsened briefl y at that 
stage, which indicates an infection 
by this bacterium. Thus, in our study, 
the incidence of I. limosus was 2.8% 
(4.9% for adults with CF and 1.2% 
for children with CF). The incidence 
of Burkholderia cepacia complex dur-
ing the same period and in the same 
patients was 2.1% (3 adults with CF 
were positive, data not shown).
The genus Inquilinus belongs 
to the α-Proteobacteria; the genus 
Azospirillum is the most closely re-
lated bacteria (2). This cluster of bac-
teria contains several strains that are 
able to grow under saline conditions 
and in biofi lms (8,9). The mucoid phe-
notype of I. limosus may contribute to 
its colonization and resistance to many 
antimicrobial drugs. Recently, the ex-
opolysaccharides (EPS) produced by I. 
limosus were studied. The authors in-
dicated that I. limosus produces main-
ly 2 EPSs that exhibit the same charge 
per sugar residue present in alginate, 
the EPS produced by Pseudomonas 
aeruginosa in patients with CF. This 
similarity may be related to common 
features of the EPS produced by these 
2 opportunistic pathogens that are re-
lated to lung infections (10). Trans-
mission of I. limosus between patients 
with CF is not known, but in the report 
from Chiron et al., 1 of the 5 patients 
with I. limosus had a brother who had 
never been colonized with this bacte-
rium despite living in the same home 
(5). Schmoldt et al. reported that 3 
patients were treated in the same out-
patient CF clinic during overlapping 
time periods and each patient was in-
fected/colonized by an individual I. li-
mosus clone, which suggests that there 
was no transmission among these pa-
tients (4). This bacterium has been re-
covered mainly from sputum of ado-
lescents (mean age 17 ± 6.47 years, 
range 8–35), except in our study with 
a 2-year-old boy, which suggests that 
this emerging bacterium may be hos-
pital acquired, as recently suggested 
(7). Because this bacterium is multire-
sistant to several antimicrobial drugs, 
particularly colistin, which is widely 
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used for treatment for P. aeruginosa 
colonization (as was the case for our 
4 patients), we hypothesize that this 
bacterium is selected during the evo-
lution of the disease. 
We have developed a real-time 
PCR molecular method that is faster 
and easier than amplifi cation-sequenc-
ing for prompt detection and accurate 
identifi cation of I. limosus with good 
specifi city and sensitivity. By using this 
screening assay, we identifi ed  4 ad-
ditional cases of patients with CF who 
were also infected with this bacterium, 
including a 2-year-old child. In addi-
tion, by using this technique, we were 
able to detect I. limosus in a patient 
with deteriorated respiratory function 3 
months before the culture-based isola-
tion, indicating that a low bacterial load, 
insuffi cient for being isolated in culture, 
can be detected by PCR in the lower re-
spiratory tract of patients with CF.
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Table. Clinical and epidemiologic features of cystic fibrosis (CF) patients with Inquilinus limosus*
Case
no.
Age,
y/sex 
Lung
transplant
Positive
samples
Clinical
manifestation,
first isolation 
Growth on 
MacConkey 
agar
Growth on 
selective
agar (d) 
Phenotypic 
identification†
Other
associated
pathogens Reference
1 22/F Yes Lung explant, 
BAL, sputum 
Pneumonia Poor ND AR PA, PM (1)
2 17/M No Sputum Stable No Yes (6 d) SP SA, PA, CA (3)
3 14/F No Sputum Stable No Yes (5 d) SP PA, AF, CA (3)
4 12/M No Sputum Stable ND Yes (ND) SP PA, SM, 
SA, AX 
(5)
5 13/F No Sputum Exacerbation ND Yes (ND) SP PA, SA, AF (5)
6 8/M No Sputum Stable ND Yes (ND) SP PA (5)
7 10/M No Sputum Stable ND Yes (ND) SP None (5)
8 18/M No Sputum Exacerbation ND Yes (ND) AR PA, SA, AF (5)
9 16/F No Sputum Severe
exacerbation 
ND ND PA PA (4)
10 19/M No Sputum Stable ND ND ND PA (4)
11 17/F No Sputum Exacerbation ND ND ND PA, CA, AF (4)
12 20/F No Sputum Exacerbation ND ND ND PA, SA, CA, 
AF
(4)
13 17/F No Sputum Stable ND ND ND PA, SA, 
SM, CA, AF
(4)
14 35/M No Sputum Respiratory 
decline
ND ND PA PA, SM, 
SMA
(4)
15 17/F No Sputum Stable No Yes (4 d) SP CA This study 
16 2/M No Sputum Productive
cough
No Yes (3 d) SP SA, HI This study 
17 21/M No Sputum Exacerbation No Yes (3 d) AR PA, AF This study 
18 15/M No Sputum Fever and 
thoracic pain 
No Yes (3 d) AR SA This study 
*BAL, bronchoalveolar lavage; ND, not determined; AR, Agrobacterium radiobacter; PA, Pseudomonas aeruginosa; PM, Proteus mirabilis; SP, 
Sphingomonas paucimobilis; SA, Staphylococcus aureus; CA, Candida albicans; AF, Aspergillus fumigatus; SM, Stenotrophomonas maltophilia; AX, 
Achromobacter xylosoxidans; SMA, Serratia marcescens; HI, Haemophilus influenzae.
†Phenotypic identification was obtained by using the BIOLOG GN MicroPlate assay (BIOLOG Inc., Hayward, CA, USA) for case 1 and the API 20NE kit 
system (bioMérieux, Marcy l’Etoile, France) for cases 2–8 and 15–18. 
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Splenic Rupture 
and Malignant 
Mediterranean 
Spotted Fever
To the Editor: Mediterranean 
spotted fever (MSF) is a Rickettsia 
conorii infection endemic to the Medi-
terranean. In this case, a 55-year-old 
man was referred to the Necker-En-
fants Malades Hospital, Paris, France, 
for fever, myalgia, and hypotensive 
shock. The patient had been in South-
ern France (Montpellier) 6 days before 
symptom onset and had been bitten by 
a tick on the left hand. Four days later, 
he reported fatigue, fever (39°C), and 
myalgia. His medical history showed 
polycystic kidney disease, which had 
necessitated hemodialysis and a kidney 
transplant. He was receiving ongoing 
treatment with an immunosuppressive 
regimen of cyclosporine, predniso-
lone, and tacrolimus; his baseline he-
moglobin level was 15 g/dL, and crea-
tinine level was 230 μmol/L.
At admission, the patient’s tem-
perature was 39.5°C, blood pres-
sure 55/40 mm Hg, and heart rate 
104 beats/min. Physical examination 
showed a diffusely tender abdomen 
with guarding, no hepatosplenom-
egaly, a nontender renal transplant, 
and no lymphadenopathy. Results of 
cardiovascular, respiratory, and neu-
rologic examinations were unremark-
able. A diffuse maculopapular cutane-
ous eruption was noted on the lower 
limbs; no eschar was detected.
Laboratory analyses showed the 
following values: hemoglobin 7.9 g/
dL, platelet count 115 × 109/L, leu-
kocyte count 6.7 × 109/L (neutrophils 
5.2 × 109/L, lymphocytes 1.4 × 109/L); 
serum creatinine 466 μmol/L, and C-
reactive protein 156 mg/L. Blood cul-
tures were negative. Serologic study 
results were negative for HIV, hepatitis 
viruses, Epstein-Barr virus, cytomega-
lovirus, Legionella, Mycoplasma, 
Coxiella, Bartonella, Leishmania, and 
Toxoplasma spp. Serologic testing ob-
tained at day 1 was negative for spot-
ted fever group (SFG) rickettsiosis.
A computed tomographic scan 
showed hemoperitoneum secondary to 
a ruptured subcapsular splenic hema-
toma (online Appendix Figure, avail-
able from www.cdc.gov/EID/content/
14/6/995-appG.htm), and an emer-
gency splenectomy was performed. 
Histopathologic evaluation of the 
spleen showed white pulp atrophy; the 
red pulp indicated congestion and ill-
defi ned nodules, varying in size and 
comprising macrophages, polymor-
phonuclear neutrophils, and necrotic 
cells (Figure, panels A, B). Skin bi-
opsy of the macular eruption on day 
2 demonstrated a leukocytoclastic 
vasculitis with nonocclusive luminal 
thrombi in the dermal capillaries (Fig-
ure, panel C).
Universal 16S rRNA gene PCR 
amplifi cation on spleen and skin tissue 
samples and direct sequencing identi-
fi ed an R. conorii–specifi c 16S rRNA 
sequence match. We confi rmed this by 
using primers for gltA and ompA spe-
cifi c for R. conorii. Immunohistochem-
ical  staining demonstrated Rickettsia 
in endothelial cells and macrophages 
in the spleen and skin (Figure, pan-
els D–F). Blood culture, skin biopsy 
specimens, and splenic tissue cultures 
were subsequently R. conorii positive. 
Doxycycline therapy (100 mg intrave-
nously twice a day) was instituted at 
day 2 because rickettsiosis was sus-
pected. The patient dramatically im-
proved within 72 hours and remained 
well 36 months after diagnosis.
MSF is a rickettsiosis belong-
ing to the tick-borne SFG caused by 
R. conorii, an obligate intracellular 
bacteria transmitted by the dog tick 
Rhipicephalus sanguineus. Endemic 
to Mediterranean countries, MSF gen-
erally results in a benign febrile ill-
ness accompanied by a maculopapular 
rash, myalgia, and local black eschar 
at a tick bite inoculation site. A minor-
ity of persons seeking treatment dis-
play a malignant form, which results 
from disseminated vasculitis associ-
ated with increased vascular perme-
ability, thrombus-mediated vascular 
occlusion, and visceral perivascular 
lymphohistiocytic infi ltrates (1). Fo-
cal thrombi have been identifi ed in 
almost all organs of patients with fatal 
cases. Manifestations of MSF include 
neurologic involvement, multi-organ 
failure, gastric hemorrhage, and acute 
respiratory distress syndrome; the 
case-fatality rate is 1.4%–5.6%.
Splenic rupture has been reported 
in the course of infection with several 
microbial agents, including Epstein-
Barr virus (2), HIV, rubella virus, Bar-
tonella spp. (3), Salmonella spp., myco-
bacteria (4), and Plasmodium spp. (5). 
Splenomegaly as a result of MSF has 
also been documented previously (6); 
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